SmartGateVC的动态

Austria: Life Science Tools M&A - European Healthcare Investor Association (E.H.I.A.) Investor Member Novo Holdings has acquired a 60% stake in Single Use Support. The two founder shareholders will retain 10% each and Danaher Corporation 20%. Value was not disclosed, but a spokesperson indicated it was a?"high triple-digit million euros" amount. Founded in 2017 in Kufstein,?Austria?by?Johannes Kirchmair ???and?Thomas Wurm, Single Use Support employs 200 people and is transforming the production process for advanced pharmaceutical modalities with its equipment and consumables used in the bioprocessing value chain. With a focus on solutions for biological drug substances, cell and gene therapies, and mRNA vaccines, the company’s customers include leading pharma companies, biotech companies and CDMOs. William Blair were financial and Kromann Reumert, DORDA Rechtsanw?lte GmbH, Linklaters and?Wilson Sonsini Goodrich & Rosati?legal advisors to Novo. Jefferies were financial and E+H Attorneys-at-Law legal advisors to Single Use Support. #healthcare #lifesceinces Johan Hueffer Real Leclerc John Duncan Park

Exciting to see that the bioprocessing industry is experiencing phenomenal growth, with the upstream bioprocessing market projected to soar from $22.79 billion in 2023 to $82.10 billion by 2032. This growth highlights an exciting reality—but also a critical challenge: producing therapeutics at the scale and quality required to meet global demand. Whether it is in the production of biologics, cell and gene therapies, or mRNA vaccines - ensuring consistency, efficiency, and scalability in production is no small task. Excited to see how these innovations continue to shape the future of healthcare! #Biotech #Bioprocessing #Innovation https://lnkd.in/eSRxfd9N

Excited by the idea of #generative biology. Generative AI has moved beyond writing poems and drafting emails. Now its being used to generate novel proteins - #DNA sequences never before seen in nature. This means medicines can be designed to fit a specific target. This dramatically increases success rates and cuts drug development timelines. Generative Biologics could be the next wave of new therapeutics. #GenAI #drugdiscovery #pharma #investing #equities https://lnkd.in/eWxQvZRt

Excited by the idea of #generative biology. Generative AI has moved beyond writing poems and drafting emails. Now its being used to generate novel proteins - #DNA sequences never before seen in nature. This means medicines can be designed to fit a specific target. This dramatically increases success rates and cuts drug development timelines. Generative Biologics could be the next wave of new therapeutics. #GenAI #drugdiscovery #pharma #investing #equities https://lnkd.in/eWxQvZRt

This afternoon at the Oligonucleotide Therapeutics & Delivery Conference, we had an electrifying panel discussion on ‘Reviewing Industry Progress and R&D for Advanced Oligonucleotide Modalities.’ The session featured insights from industry experts: ?? Peter D Smith, Director, New Modalities Chemistry, AstraZeneca ?? Thierry Dorval, Head of Data Sciences & Data Management, Servier Pharmaceuticals ?? Marco Mina, Director, Head of Comp Bio & Data Science, HAYA Therapeutics This discussion covered: - Antisense oligonucleotides – the next chapter: How have we seen R&D evolve in recent years with more funding in genetic medicine and increased regulatory approvals -Technologies driving drug discovery: exploring how AI is being utilized to unlock drug discovery of oligonucleotide therapeutics -From proof of concept to oligonucleotide-based therapies how are CMC practices developing to match the acceleration in R&D A huge thanks to our panelists for a truly insightful discussion! Stay tuned for more! Exhibitors: Aptamer Group | Asymchem Group | ChemGenes #OligoTherapeutics #OligoResearch #NucleicAcidTherapeutics #GeneTherapy #RNAi #ASOs #Biotechnology #PrecisionMedicine #PharmaInnovation #TherapeuticDevelopment #Biopharma #GeneticMedicine #MolecularBiology #OligoTx

? MilliporeSigma: Top CDMO Performer in 2023 ?? ?? Despite a tough year for biopharma, MilliporeSigma/Merck Group achieved impressive growth in 2023 with revenue reaching $864.8 million. ?? While industry leaders are navigating budget cuts and regulatory changes, there's growing optimism around emerging modalities like gene therapies and antibody-drug conjugates. MilliporeSigma continues to be at the forefront, supporting these advancements with cutting-edge biosafety and characterization testing. ?? Want to know how we can support your development programs with the latest in biosafety testing? ?? Learn more at https://lnkd.in/ecEFiFHn ?? Read more in GEN magazine (September 2024): https://lnkd.in/d7rDzamt #biopharma #biotechnology #pharmaindustry #drugdevelopment #manufacturing #CDMO #MilliporeSigma #BiosafetyTesting

This afternoon at the Oligonucleotide Therapeutics & Delivery Conference, we had an electrifying panel discussion on ‘Reviewing Industry Progress and R&D for Advanced Oligonucleotide Modalities.’ The session featured insights from industry experts: ?? Peter D Smith, Director, New Modalities Chemistry, AstraZeneca ?? Thierry Dorval, Head of Data Sciences & Data Management, Servier Pharmaceuticals ??Marco Mina, Director, Head of Comp Bio & Data Science, HAYA Therapeutics This discussion covered: - Antisense oligonucleotides – the next chapter: How have we seen R&D evolve in recent years with more funding in genetic medicine and increased regulatory approvals -Technologies driving drug discovery: exploring how AI is being utilized to unlock drug discovery of oligonucleotide therapeutics -From proof of concept to oligonucleotide-based therapies how are CMC practices developing to match the acceleration in R&D A huge thanks to our panelists for a truly insightful discussion! Stay tuned for more! Exhibitors: Aptamer Group | Asymchem Group | ChemGenes #OligoTherapeutics #OligoResearch #NucleicAcidTherapeutics #GeneTherapy #RNAi #ASOs #Biotechnology #PrecisionMedicine #PharmaInnovation #TherapeuticDevelopment #Biopharma #GeneticMedicine #MolecularBiology #OligoTx

Thoughts on this? >> Latus Bio launches with $54 million in Series A financing - The Pharma Letter >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #competitivemarketing #healthcare #biotech #pharmaceutical #pharma

? ?????? ???? ?????????? ???? ???????? ?????????????? ?? ?? 2023 was a challenging year for biopharma companies. However, leading CDMOs* managed to achieve impressive growth, with their combined revenue climbing 7% in 2023: 1?? Lonza ? $7.73 billion 2?? Thermo Fisher Scientific ? $6.967 billion 3?? Catalent Pharma Solutions ? $4.135 billion 4?? Samsung Biologics ? $2.695 billion 5?? WuXi Biologics ? $2.373 billion 6?? Siegfried ? $1.463 billion 7?? Recipharm ? $1.442 billion 8?? FUJIFILM Diosynth Biotechnologies ? $1.376 billion 9?? Boehringer Ingelheim ? $1.191 billion ?? MilliporeSigma/ Merck Group ? $864.8 million ?? While industry leaders are facing uncertainties due to budget cuts and regulatory changes, there’s still optimism for emerging modalities like gene therapies and antibody-drug conjugates! *??????????: ???????????????? ?????????????????????? ?????? ?????????????????????????? ?????????????????????????? ?? Read more ? GEN magazine (September 2024): https://lnkd.in/d7rDzamt Genetic Engineering & Biotechnology News #biopharma #biotechnology #pharmaindustry #drugdevelopment #manufacturing #CDMOs #CRO #CMO

A nice overview. To my humble view, the trend, beyond biologics market growth, is that external supply remains a strong option and a key element of network strategies both in development and commercial supply.